Myriad Genetics and SOPHiA GENETICS Announce Strategic Collaboration for Global Liquid Biopsy Companion Diagnostic Development
Reuters
Sep 23
Myriad Genetics and SOPHiA GENETICS Announce Strategic Collaboration for Global Liquid Biopsy Companion Diagnostic Development
Myriad Genetics Inc., a prominent player in molecular diagnostic testing and precision medicine, has announced a strategic collaboration with SOPHiA GENETICS, an AI technology company focused on transforming precision medicine. The partnership aims to develop and provide innovative global liquid biopsy companion diagnostic (CDx) tests for pharmaceutical companies. Leveraging Myriad's advanced laboratory capabilities in the U.S. and SOPHiA GENETICS' extensive network of over 800 institutions in more than 70 countries, the collaboration will focus on the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDM™. This test, developed in collaboration with Memorial Sloan Kettering Cancer Center, utilizes proprietary algorithms to analyze circulating tumor DNA from a single blood draw, aiming to expand access to personalized healthcare. Myriad and SOPHiA GENETICS will manage regulatory submissions in the U.S. and internationally, respectively, to ensure global availability.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9533277-en) on September 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.